Search the Newsreel

VivoSim Labs Sets 2026 Annual Shareholder Meeting Date

VivoSim Labs (VIVS) announced that its 2026 Annual Meeting of Stockholders will take place on September 30, 2026, with August 13, 2026, designated as the record date. The meeting date was moved up by over 30 days compared to the previous year, necessitating an …

Enterprise value to EBIT forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS

The article discusses the enterprise value to EBIT forward for Vivos Therapeutics, Inc. (NASDAQ:VVOS). It highlights financial data related to the company, indicating the current period value, changes, and percentage changes, provided by FactSet Research Systems Inc. and ICE Data Services.

Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis

Vivos Therapeutics Inc (VVOS) currently holds a weak financial score of 5.33, ranking 196 out of 199 in the Healthcare Equipment & Supplies industry, indicating low operating efficiency. Despite its weak financial status, the company reported significant year-over-year growth in its latest quarterly revenue …

VivoSim Labs announces 2026 annual shareholder meeting

VivoSim Labs has announced its 2026 annual stockholders meeting will be held in San Diego on September 30, 2026. The meeting will include the election of directors, with a deadline for shareholder nominations set for August 9, 2026. This news brief was generated by …

Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Vivos Therapeutics Inc (VVOS), focusing on its support and resistance levels, key indicators, and moving averages. According to the analysis, VVOS has a current price momentum score of 5.17, trading between a resistance level of $0.51 and …

Vivos Therapeutics Inc (VVOS) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Vivos Therapeutics Inc (VVOS). It provides key financial data for VVOS, including its market cap and recent stock performance. The article details institutional shareholdings and recent changes in those holdings, highlighting specific investors and …

Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Vivos Therapeutics Inc (VVOS) as of April 6, covering business segments for FY2025Q3. The company's main revenue streams include sleep testing services, appliance sales to integrated providers, and center revenue, along with smaller contributions from sponsorships, …

VVOS|Vivos Therapeutics Inc|Price:0.390|Chg%:-0.013

This article provides a comprehensive stock analysis of Vivos Therapeutics Inc (VVOS) from TradingKey, highlighting its financial health, growth potential, valuation, and analyst ratings. The company is focused on medical technology for sleep wellness, particularly obstructive sleep apnea. Despite solid past revenue growth, the …

VivoSim Labs, Inc. Revenue Breakdown – NASDAQ:VIVS

This article provides a revenue breakdown for VivoSim Labs, Inc. (NASDAQ: VIVS), highlighting that the United States was the primary contributor to its revenue for the past two years. The company generated $131,000 USD from the US last year, a decrease from $144,000 USD …

Vivos Therapeutics Inc (VVOS) Cash Flow

This article provides a detailed cash flow statement for Vivos Therapeutics Inc (VVOS), covering quarterly and annual data for various cash flow activities including operating, investing, and financing. It also includes key financial metrics like net income, capital expenditures, and free cash flow, alongside …

Vivos Therapeutics, Inc. Revenue Breakdown – NASDAQ:VVOS

This article provides a detailed revenue breakdown for Vivos Therapeutics Inc (VVOS) as of April 6, covering business segments for FY2025Q3. The company's main revenue streams include sleep testing services, appliance sales to integrated providers, and center revenue, along with smaller contributions from sponsorships, …

Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Vivos Therapeutics Inc (VVOS) from TradingKey. It shows that VVOS has not distributed dividends in the past five years but underwent a 25-to-1 merger-related stock split on October 26, 2023. The page also displays …

VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard

VivoSim Labs (VIVS) received a notice from Nasdaq for failing to meet the Listing Rule 5550(b)(1) requiring $2.5 million in stockholders' equity. The company has 45 days to submit a compliance plan, with a possible extension, and trading remains unaffected. VivoSim Labs has reported …

Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Vivos Therapeutics Inc (VVOS), identifying major individual and corporate shareholders, and providing a breakdown of shareholder types. It also presents institutional shareholding data over several quarters, including the number of institutions, shares held, and proportional changes. Additionally, …

VIVS|VivoSim Labs Ord Shs|Price:0.446|Chg%:-0.015

This article provides a detailed financial overview of VivoSim Labs Ord Shs (VIVS), including its current stock price, market capitalization, key financial figures, and recent performance trends. It also lists technical indicators, moving averages, and major shareholders. The company's EPS and total revenue data …

VivoSim Labs (VIVS) Holds Steady Near Support at $0.45 Amid Low Volatility - Sentiment Divergence

Two Chinese firms place VivoSim's first paid mainland orders

VivoSim (Nasdaq: VIVS) has announced its first commercial sales in mainland China for its NAMkind™ liver and gastrointestinal toxicology screening and efficacy testing services. Secured through distributor Tekon, these initial paid programs with a Shanghai oncology biotech and a Chengdu pharmaceutical company represent a …

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

VivoSim Labs, Inc. announced its first commercial sales in China for its NAMkind™ toxicology screening and efficacy testing services, marking a significant expansion into the world's second-largest pharmaceutical market. The initial engagements involve a Shanghai-based oncology biotech and a Chengdu-based pharmaceutical company, secured through …

VivoSim Labs raises $4M in private placement By Investing.com

VivoSim Labs, Inc. has raised approximately $4.0 million through a private placement with a healthcare-focused institutional investor, selling shares and warrants at $0.85 per share. The company will use the net proceeds for working capital and general corporate purposes. This comes alongside recent news …

Vivos Therapeutics (VVOS) Stock Fair Value Falls After Analyst Target Cuts

Vivos Therapeutics' (VVOS) fair value estimate has been reduced from US$2.45 to US$2.12 per share, reflecting analyst concerns over balance sheet reinforcement and potential equity dilution. Despite some analysts still seeing value, the updated targets are influenced by the need for significant capital raising …

VivoSim Labs, INC. FY 2026: Revenue $0.13M, Net loss $13.84M, EPS $(5.35) — 10-K Summary

VivoSim Labs, INC. reported its fiscal year 2026 results, showing flat revenue at $0.13M compared to $0.14M in FY 2025. The company experienced a significant increase in net loss, reaching $13.843M from $2.488M the previous year, with diluted loss per share at $(5.35) versus …

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

VivoSim Labs Inc. announced a $4.0 million private placement with a single healthcare-focused institutional investor. The deal involves the sale of 4,705,883 shares of common stock and warrants at a combined price of $0.85 per share. Additionally, existing May 2024 warrants will have their …

VivoSim Labs prices USD 4 million private placement at USD 0.85 per share

VivoSim Labs has priced a $4 million private placement at $0.85 per share and warrant with a single healthcare-focused institutional investor. The deal includes 4,705,883 common shares and warrants, with the warrants becoming exercisable after shareholder approval and expiring in five years. Additionally, existing …

VivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant Amendment

VivoSim Labs has secured $4.0 million through a private placement with a healthcare-focused institutional investor, involving the sale of common stock and warrants at $0.85 per share. Existing warrants will also be amended to lower their exercise price to $0.85, subject to shareholder approval. …

VivoSim Labs raises $4M in private placement

VivoSim Labs (NASDAQ:VIVS) has raised approximately $4.0 million through a private placement with a healthcare-focused institutional investor, selling shares and warrants at $0.85 per share. The company will use these proceeds for working capital and general corporate purposes. This funding follows recent positive developments, …

Investor group takes 19.9% position in Vivos Therapeutics (VVOS)

An investor group, including V-CO Investors LLC and Michael C. Skaff, has reported a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. (VVOS), totaling 2,783,102 common shares. This position stems from a $1.6 million subscription by V-Co 4, which included the conversion of a …

VivoSim Labs, Inc. announced that it expects to receive $4.000001 million in funding

VivoSim Labs, Inc. has announced a securities purchase agreement with a healthcare-focused institutional investor for $4,000,000.55 in gross proceeds. This funding involves the sale of 4,705,883 common shares and pre-funded warrants, with an issue price and exercise price of $0.85 per share. The closing …

VivoSim Labs Sees FY27 Rev Growing Significantly >VIVS

VivoSim Labs (VIVS) projects significant revenue growth for fiscal year 2027. The company's outlook indicates a strong financial performance in the coming years. This forecast suggests positive momentum for VIVS.

VivoSim Gains on Revenue Word

VIVS Stock Whipsaws As Traders Target Volatile Moves

VivoSim Labs (NASDAQ:VIVS) hits $5M milestone; company says 500% revenue jump comes off $131K base

Why Vivosim Labs Shares Are Rocketing on Wednesday?

VivoSim Labs Inc. (NASDAQ: VIVS) shares surged on Wednesday due to a $5 million milestone payment received from Eli Lilly and Company (NYSE: LLY) and optimistic revenue guidance for FY2027, anticipating over 500% growth. The payment was triggered by the first patient being dosed …

Vossloh AG: Solide vorläufige Ergebnisse für das zweite Quartal; Prognosekürzung; Schätzungen und Kursziel gesenkt; KAUFEN beibehalten.

EQS-Adhoc: Vossloh Aktiengesellschaft: Anpassung der Umsatz- und Ergebnisprognose für das Geschäftsjahr 2026

Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions

VVOS Forecast — Price Target — Prediction for 2027